A recent retrospective Italian study, including 153 patients with ECOG 2 and PD-L1 ≥ 50% NSCLC treated with pembrolizumab, also underscored the prognostic relevance of performance status. This evidence concerns the gene CD274 and non-small cell lung carcinoma.